Press release
Investigation announced for Investors in NYSE: SQZ shares over possible Wrongdoing at SQZ Biotechnologies Company
An investigation on behalf of investors in SQZ Biotechnologies Company (NYSE: SQZ) shares over potential wrongdoing.
Investors who purchased shares of SQZ Biotechnologies Company (NYSE: SQZ) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain SQZ Biotechnologies directors breached their fiduciary duties and caused damage to the company and its shareholders.
Watertown, MA based SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. SQZ Biotechnologies Company reported that its annual Total Revenue rose from $20.99 million in 2020 to $27.09 million in 2021, and that its Net Loss increased from $50.52 million in 2020 to $68.74 million in 2021.
On or around October 29, 2022, SQZ Biotechnologies Company conducted its initial public offering ("IPO"), selling 4,411,765 shares priced at $16.00 per share.
Then, on December 1, 2022, SQZ Biotechnologies Company issued a press release "announc[ing] that Armon Sharei, PhD, Chief Executive Officer at SQZ Biotechnologies, will step down from his role as CEO and the Board of Directors, effective immediately," and that the Company will reduce its workforce by roughly 60% as it "pause[s] its APC, Activating Antigen Carrier (AAC) and Tolerizing Antigen Carrier (TAC) programs."
Shares of SQZ Biotechnologies Company (NYSE: SQZ) declined to as low as $1.41 per share on December 5, 2022.
Those who purchased shares of SQZ Biotechnologies Company (NYSE: SQZ) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in NYSE: SQZ shares over possible Wrongdoing at SQZ Biotechnologies Company here
News-ID: 2936970 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for SQZ
Human papillomavirus Associated Cancer Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Human papillomavirus (HPV) Associated Cancer Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Human papillomavirus (HPV) Associated Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Human…
Advancing the Treatment Landscape: In-Depth Analysis of Type 1 Diabetes Pipeline …
DelveInsight's, "Type 1 Diabetes Pipeline Insight 2023" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Type 1 Diabetes pipeline landscape. It covers the Type 1 Diabetes pipeline drug profiles, including Type 1 Diabetes clinical trials and nonclinical stage products. It also covers the Type 1 Diabetes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline…
Type 1 Diabetes Drugs Analysis, (2023 Updates): Clinical Trials, Treatment Thera …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Type 1 Diabetes pipeline constitutes 80+ key companies continuously working towards developing 100+ Type 1 Diabetes treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Type 1 Diabetes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Human papillomavirus (HPV) Associated Cancer Pipeline Analysis Demonstrates Nove …
DelveInsight's, "Human papillomavirus (HPV) Associated Cancer Pipeline Insight, 2023," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Human papillomavirus (HPV) Associated Cancer pipeline landscape. It covers the Human papillomavirus (HPV) Associated Cancer pipeline drug profiles, including Human papillomavirus (HPV) Associated Cancer clinical trials and nonclinical stage products. It also covers the Human papillomavirus (HPV) Associated Cancer pipeline therapeutics assessment by product type, stage, route of administration,…
Investigation announced for Investors in shares of SQZ Biotechnologies Company ( …
An investigation was announced for investors of SQZ Biotechnologies Company (NYSE: SQZ) shares over potential securities laws violations by SQZ Biotechnologies Company.
Investors who purchased shares of SQZ Biotechnologies Company (NYSE: SQZ), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of SQZ Biotechnologies Company (NYSE: SQZ)…
The Type 1 Diabetes Market Size is anticipated to increase during the study peri …
With the expected launch of emerging therapies, the Type 1 Diabetes market is expected to show positive growth in the forecast period in the 7MM. Moreover, increased awareness of Type 1 Diabetes has amplified drug research and development.
The Type 1 Diabetes market report provides current treatment practices, emerging drugs, Type 1 Diabetes market share of the individual therapies, current and forecasted Type 1 Diabetes Market Size from 2019 to…
